Scientists Invent Electric Comb That Triggers Rapid Hair Growth in Mice

Beihang University’s Detangle comb prototype hit 97.85% regrowth in mice, but human trials have not begun

Rex Edison Avatar
Rex Edison Avatar

By

Image: Wikimedia Commons

Key Takeaways

Key Takeaways

  • Beihang University’s Detangle device achieved 97.85% hair regrowth in treated mice using combined therapies.
  • Electroporation drives genetic therapies up to nine times deeper than conventional topical application.
  • Detangle remains a lab prototype, with no human trials confirming safety or effectiveness.

Researchers built a comb-shaped bioelectronic device that combines electrical stimulation with genetic therapies. In a mouse model, the full treatment achieved approximately 97.85% hair coverage in the treated area. The gap between that result and a treatment for human baldness remains significant.

A Prototype Built Like a Comb, Engineered Like a Drug Delivery System

Beihang University’s Detangle device looks like a comb but functions as a targeted biological delivery system.

Researchers at Beihang University developed Detangle, a device with electrodes embedded in teeth of alternating heights and integrated drug-loading modules. The design generates a localized electric field intended to stimulate hair follicles and improve delivery of therapeutic molecules into follicular tissue.

Two Mechanisms Drive the Treatment

Pulsed electricity does two jobs: it stimulates follicles directly and temporarily opens cell membranes to improve drug uptake.

The alternating teeth create pulsed electrical stimulation that act on hair follicles in the treated skin of the mice. Those same pulses temporarily increase cell-membrane permeability through a process called electroporation, briefly opening pores in cell walls so genetic therapies can enter cells more effectively.

The reported penetration depth reached up to roughly nine times deeper than conventional topical application, according to the study published in Nature Communications.

Two Targeted Therapies, Two Specific Jobs

The genetic treatments address two biological pathways the researchers targeted: blood-vessel formation and androgen signaling.

One therapy, a VEGFA plasmid, is designed to promote blood-vessel formation around follicles. The other, an SRD5A2 siRNA, targets an enzyme involved in androgen signaling. That enzyme contributes to the androgen pathway implicated in the follicle miniaturization that characterizes androgenetic alopecia.

The Mouse Numbers Are Striking

Every treatment condition outperformed the control, and the full combination came close to complete regrowth in the treated area.

Male mice with testosterone-induced hair loss served as the model. Untreated animals recovered about 1% of hair coverage on the shaved experimental area after 28 days, per Nature Communications.

Electrical stimulation alone produced roughly 40% regrowth, while finasteride reached approximately 50%. Topical minoxidil achieved about 70%.

Adding SRD5A2 siRNA to electrical stimulation brought regrowth to approximately 85%, and pairing stimulation with the VEGFA plasmid reached about 90%. The full combination of electrical stimulation, VEGFA plasmid, and SRD5A2 siRNA reached approximately 97.85%, according to Nature Communications. The study abstract frames that result as improvement from roughly 70% with topical minoxidil to nearly 100% within one month in the mouse model.

The Limitation Is the Story

Mice are not people, and testosterone-induced hair loss in a lab animal is not equivalent to human androgenetic alopecia.

Detangle has not been tested in humans. Mouse skin, hair-cycle timing, and follicle biology differ substantially from human tissue, and results from an induced mouse model cannot establish whether the device is safe, tolerable, or effective in people.

Long-standing, genetically influenced hair loss in humans involves a more complex biological picture than testosterone-induced shedding in a mouse.

What the Study Actually Establishes

This is a proof of concept for combining physical stimulation with targeted molecular delivery, not a product announcement.

The research demonstrates a method for combining physical stimulation with targeted molecular delivery, an approach that may warrant further investigation. Human trials and dose optimization would be required before any clinical use. That process would also need to cover safety questions including skin irritation, immune response, electroporation effects, and potential unintended gene-expression changes. Full regulatory review would follow before clinical use could begin.

Detangle is a laboratory prototype. There is no evidence in available sources that it is commercially available or approved for treating hair loss in any population.

Share this

At Gadget Review, our guides, reviews, and news are driven by thorough human expertise and use our Trust Rating system and the True Score. AI assists in refining our editorial process, ensuring that every article is engaging, clear and succinct. See how we write our content here →